**Ward IV of the Gastrointestinal Oncology Center, Peking University Cancer Hospital** As a benchmark department in the field of gastrointestinal tumor diagnosis and treatment in China, Ward IV of the Gastrointestinal Oncology Center at Peking University Cancer Hospital has adhered to the core development philosophy of "Precision Diagnosis and Treatment, Minimally Invasive Leadership, and Discipline Integration" since its establishment. It has built a high-level diagnosis and treatment platform integrating medical care, education, and research. The department was founded in 2009 by Professor Su Xiangqian, a renowned gastrointestinal surgery expert in China. It was the first minimally invasive gastrointestinal oncology surgery department in a national cancer specialty hospital, pioneering the standardized treatment of minimally invasive surgery for gastrointestinal tumors in China. **Core Diagnostic and Treatment Directions & Featured Technologies** The department focuses on the precise diagnosis and treatment of digestive tract tumors, including gastric cancer, colorectal cancer, adenocarcinoma of the esophagogastric junction, and gastrointestinal stromal tumors (GISTs), forming several nationally leading featured technology systems. In terms of treatment models, it vigorously promotes the multidisciplinary team (MDT) model, integrating experts from surgery, internal medicine, radiation oncology, and radiology to formulate individualized treatment plans for patients. Regarding technical features, laparoscopic radical minimally invasive surgery is the core. The department proficiently performs various types of minimally invasive gastrointestinal tumor surgeries, achieving an organic unity of radical tumor resection and minimally invasive functional preservation. Simultaneously, it has accumulated extensive experience in neoadjuvant therapy, conversion therapy, and comprehensive treatment for advanced tumors, significantly improving patient survival rates. In recent years, the department has routinely performed various types of robotic minimally invasive surgeries using the latest robotic surgical systems. Leveraging the magnified three-dimensional vision and precise, flexible robotic arms of these systems, it achieves precise tumor resection and functional preservation, providing patients with safer and more precise cutting-edge surgical options. **Medical Team Size and Strength** The department brings together a high-quality medical team with a reasonable structure and superb skills. It currently comprises 4 Chief Physicians, 6 Associate Chief Physicians, 6 Attending Physicians, 1 Principal Investigator, and 2 Associate Principal Investigators, all holding doctoral degrees. Team members have undergone rigorous specialized training and possess profound expertise in minimally invasive gastrointestinal tumor surgery and complex case management. They also undertake research and teaching tasks for Peking University Health Science Center, training a large number of oncology professionals. The department has undertaken multiple national and provincial/ministerial-level research projects. Since its establishment, focusing on laparoscopic and robot-assisted surgery for gastric and colorectal cancer, it has led or participated in numerous domestic and international multicenter randomized controlled clinical trials (including the CLASS series, RESOLVE series, ADDICT study, LASRE study, RELARC study, LISH study, etc.). Relevant research results have been published in top international medical journals such as the *Journal of Clinical Oncology (JCO)*, *Lancet Oncology*, and the *Journal of the American Medical Association (JAMA)*. Department members have participated in the compilation of several academic works and have trained over 30 master's and doctoral students. The department's translational medicine team possesses both clinical depth and research height. Relying on the disciplinary platform of Ward IV, it follows the core development pathway of "Molecular Mechanism Decoding - Biomarker Translation - Precision Diagnosis and Treatment Implementation," achieving remarkable results in the field of basic research and clinical translation of digestive tract tumors. Since the department's inception, it has cumulatively secured 13 projects from the National Natural Science Foundation of China and 5 projects from the Beijing Municipal Natural Science Foundation, with a total cumulative research funding of over 14 million RMB, providing solid research support for the department's development philosophy of "Precision Diagnosis and Treatment and Discipline Integration." **Academic Status and Honors** As a pioneer in minimally invasive treatment for gastrointestinal tumors in China, the department enjoys a high reputation in the academic field. It serves as a National Training Base for Standardized Diagnosis and Treatment of Gastrointestinal Tumors and is the undertaking unit for multiple national-level research projects. The team has led or participated in the formulation of several domestic guidelines for the diagnosis and treatment of gastrointestinal tumors, and its scientific research achievements have been repeatedly published in top-tier international academic journals. Leveraging the disciplinary platform of Peking University Cancer Hospital, the department engages in in-depth cooperation with top-tier medical institutions both domestically and internationally, such as the National Cancer Center (NCC) of South Korea and Zhongshan Hospital affiliated with Fudan University, to advance the development of diagnostic and treatment technologies. The department emphasizes the construction of medical humanities and care, adhering to the philosophy of "Meticulous Treatment, Sincere Help, and Empathetic Comfort," and wholeheartedly serves every patient. It has been awarded the title of "Demonstration Ward for Medical Humanities Construction in Beijing Municipal Hospitals." Always patient-centered, the department provides comprehensive, full-cycle health protection for patients with gastrointestinal tumors through its advanced technology, high-quality service, and outstanding academic level, continuously leading the high-quality development of gastrointestinal tumor diagnosis and treatment in China.